CEWE Stiftung & Co. KGaA

  • WKN: 540390
  • ISIN: DE0005403901
  • Land: Deutschland

Nachricht vom 18.10.2021 | 12:47

CEWE Stiftung & Co. KGaA: Release of a capital market information

CEWE Stiftung & Co. KGaA / Share buy-back - 7th Interim Report
18.10.2021 / 12:47
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Release of a capital market information

CEWE Stiftung & Co. KGaA:
Share buy-back - 7th Interim Report


Announcement according to Art. 5 Section 1 b, Section 3 of regulation (EU) No. 596/2014 and Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052

Oldenburg, 18 October 2021. CEWE Stiftung & Co. KGaA (SDAX, ISIN: DE 0005403901) has bought back own company shares on the stock exchange since 1 September 2021. The repurchase is based on authorisation granted at the Annual General Meeting of 31 May 2017 to acquire up to 10 % of the company's own shares. The repurchase of shares will be exercised independently and without the influence of the company by Baader Bank AG, Munich, upon application of the safe harbour regulations.

In the period from 11 October 2021 up to and including 15 October 2021 a total of 8,032 shares were acquired as part of a share buy-back:

Date Shares bought back [units] Average price
[euros]
Volume
[euros]
11.10.2021 1,560 119.76923 186,840.00
12.10.2021 1,656 120.14734 198,964.00
13.10.2021 2,000 118.82500 237,650.00
14.10.2021 1,316 119.87812 157,759.60
15.10.2021 1,500 120.27040 180,405.60
 

The total number of shares purchased so far as part of this share buy-back from 1 September 2021 up to and including 15 October 2021 therefore amounts to 32,732 shares.

Detailed information on the transactions pursuant to Art. 2 para. 3 of Delegated Regulation (EU) 2016/1052 is available on the website of CEWE Stiftung & Co. KGaA at company.cewe.de under section Investor Relations / Corporate Governance / Share buy-back.

Should you have any queries, please contact:
CEWE Stiftung & Co. KGaA
Axel Weber (Head of Investor Relations)
email: IR@cewe.de



18.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

FORTEC Elektronik Aktiengesellschaft

Original-Research: FORTEC Elektronik AG (von Montega AG): Kaufen

29. November 2021